Pfizer (PFE) Gets FDA Nod for Pneumococcal Vaccine Prevnar 20
Pfizer PFE announced that the FDA has granted approval to its 20-valent pneumococcal conjugate vaccine for the prevention of invasive disease and pneumonia in adults. The vaccine will be marketed by the brand name of Prevnar 20.
Prevnar 20 includes all the 13 serotypes contained in Pfizer’s popular 13-valent pneumococcal conjugate vaccine, Prevnar 13 along with seven additional serotypes, which account for 40% of pneumococcal disease cases and deaths in theUnited States. This way it covers more serotypes responsible for the majority of invasive pneumococcal disease and pneumonia than any other marketed vaccine or those in clinical development.
The biologics license application (BLA) seeking approval for Prevnar 20 was based on data from three phase III studies, which involved 6,000 adult participants including older adults (65 years of age and older), vaccine-naïve adults, and adults with prior pneumococcal vaccination.
Pfizer’s stock has risen 5.6% this year so far compared with an increase of 6.1% for the industry.
Image Source: Zacks Investment Research
Pfizer, last month, initiated a study to investigate co-administration of Prevnar 20, following a booster dose of it and partner BioNTech’s BNTX COVID-19 vaccine in adults 60 years and older.
Please note that Merck’s MRK 15-valent pneumococcal conjugate vaccine candidate, V114, is under review in United States and EU. The FDA’s decision is expected on Jul 18. Merck’s phase III clinical development program for V114 includes 16 late-stage studies that evaluated the vaccine candidate in a variety of populations who are at increased risk for pneumococcal disease.
Pfizer currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy)stocks here.
A better-ranked large cap pharma stock is Bayer BAYRY with a Zacks Rank of 2(Buy). The stock has risen 8.7% this year so far.
Its earnings estimate for 2021 has gone up from $1.74 per share to $1.80per share while that for 2022 has risen from $1.89 per share to $2.00 per share over the past 30 days.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report
BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
